Ministry of Health and Family Welfare
India tests a new record- nearly 9 lakh tested in one day
Record Highest Single Day Recoveries of 57,937
Total Recoveries exceed Active Cases by more than 13 lakh
Posted On: 18 AUG 2020 1:21PM by PIB Delhi
India has set another record in
COVID-19 tests conducted per day. Nearly 9 lakh (8,99,864) testes have been
conducted in a single day, the highest tests/day so far. With this, the
cumulative tests have reached 3,09,41,264.
Even with such a high level of
testing, the positivity has remained low i.e. 8.81% compared to the weekly
national average i.e. 8.84%.
India has also recorded the
highest single day recoveries of 57,937 in the last 24 hours. This is higher
than the confirmed cases added during the same period (55,079). With more
patients recovering and being discharged from hospitals and home isolation (in
case of mild and moderate cases), the total recoveries have reached nearly 20
lakh (19,77,779). With this the gap between the recovered patients and the
active cases has crossed 13 lakh today (13,04,613).
Continuous increase in average
daily recoveries has led to India's Recovery Rate touching 73.18% and a low
Case Fatality Rate (1.92%). As a result of collaborative and focussed efforts
by the Centre and State/UT governments built on effective implementation of the
TEST, TRACK, TREAT strategy of the Union Government, 30 States/UTs are
reporting lower CFR than the national average. Aggressive TESTING leads to
early identification and isolation of positive cases. This coupled with
efficient clinical treatment has ensured a law Fatality Rate down.
The actual case load of the country i.e. the active cases (6,73,166), is only 24.91% of the total positive cases. This figure is also exhibiting a steady downward trajectory.
An ever expanding national
network of diagnostic labs has ensured the exponentially growing number of
tests being conducted across the country. As on date, 1476 total labs are
operational with 971 labs in the government sector and 505 private labs. These
include:
• Real-Time
RT PCR based testing labs: 755 (Govt: 450 + Private: 305)
• TrueNat based testing labs: 604
(Govt: 487 + Private: 117)
• CBNAAT based testing labs: 117
(Govt: 34 + Private: 83)
For all authentic & updated
information on COVID-19 related technical issues, guidelines & advisories
please regularly visit: https://www.mohfw.gov.in/ and @MoHFW_INDIA.
Technical queries related to
COVID-19 may be sent to technicalquery.covid19@gov.in and other queries on ncov2019@gov.in
and @CovidIndiaSeva .
In case of any queries on
COVID-19, please call at the Ministry of Health & Family Welfare helpline
no.: +91-11-23978046 or 1075 (Toll-free). List of helpline numbers of
States/UTs on COVID-19 is also available at
https://www.mohfw.gov.in/pdf/coronvavirushelplinenumber.pdf.
****
MV/SJ
(Release ID: 1646637) Visitor Counter : 115
Ministry of Health and Family Welfare
Dr. Harsh Vardhan inaugurates the Thalassemia Screening
and Counselling Centre at Indian Red Cross
Posted On: 18 AUG 2020 5:58PM by PIB Delhi
Dr Harsh Vardhan, Union Minister of
Health & Family Welfare inaugurated a Thalassemia Screening and
Counselling Centre at Indian Red Cross Society’s National Headquarters (IRCS
NHQ) Blood Bank, here today.
Expressing happiness at the starting of the Centre, Dr.
Harsh Vardhan lauded efforts of Indian Red Cross. Initiatives such as
these “will enable us in educating the common people on prevention of this
disease”, he added.
The Union Health Minister stated that
there are around 270 million Thalassemia patients in the world. India has the
largest number of children with Thalassemia major in the world, about 1 to 1.5
lakhs, and about 10,000 -15,000 children having Thalassemia major are born
every year. The only cure available for such children is bone marrow
transplantation (BMT). However, BMT is difficult and not affordable by the
parents of all these children. Therefore, the mainstay of treatment is repeated
blood transfusions, followed by regular iron chelation therapy to remove the
excessive iron overload, consequent to the multiple blood transfusions.
Dr Harsh Vardhan stated that this new
initiative of IRCS will provide a golden opportunity to administer adequate
therapy to those affected enabling them lead a better life and preventing the
birth of children affected with hemoglobinopathies, through carrier screening,
genetic counselling and prenatal diagnosis. “This program will aid in
prevention of birth of children affected with hemoglobinopathies, through well
planned screening programs, information dissemination and awareness generation
activities and help avert the imminent threat of this genetic disorder turning
into a major health problem. With these progressive initiatives, we shall soon
be able to achieve the New India being envisioned by the Prime Minister by
2022”, he stated.
Haemoglobinopathies, such as
Thalassemia and sickle cell disease are inherited disorders of red blood cells
and are preventable. These illnesses are chronic, life impairing and in some
cases, life threatening and impose a heavy emotional and financial burden on
families. In India, Thalassemia Major (TM) and the severe form of Thalassemia
Intermedia (TI) constitute the major burden of disease. Both are commonly
managed by regular lifelong blood transfusions and regular iron chelation.
These Thalassemia syndromes are caused by inheritance of abnormal (beta)
Thalassemia genes from both parents or abnormal beta-Thalassemia gene from one
parent and abnormal variant haemoglobin gene (HbE, HbD) from the other parent.
Shri R. K. Jain, Secretary General,
IRCS and representatives of IRCS, Thalassemics India and the health Ministry
were also present at the inauguration.
****
MV/SJ
HFW/HFM IRC visit/18Aug2020/2
(Release ID: 1646731) Visitor Counter : 17
Ministry of Health and Family Welfare
National Expert Group on Vaccine
Administration meets the Domestic Vaccine Manufactures
Posted On: 17 AUG 2020 7:53PM by PIB Delhi
The National Expert Group on
Vaccine Administration today met leading domestic vaccine manufactures- Serum
Institute of India, Pune; Bharat Biotech, Hyderabad; Zydus Cadila, Ahmedabad;
Gennova Biopharmaceuticals, Pune; and Biological E, Hyderabad.
The meeting was mutually
beneficial and productive.
It provided the National Expert
Group with inputs about the present stage of various candidate vaccines being
developed by the indigenous manufacturers as well as their expectations from
the Union Government.
****
MV
HFW/COVID Vaccine group meeting/17thAugust/4
(Release ID: 1646506) Visitor Counter : 350
No comments:
Post a Comment